Trial · NCT07361991
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
NCT07361991, Phase 1, Phase 2, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer. Trials, record NCT07361991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07361991
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
- NCT number
- NCT07361991
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Conditions
- Advan'ce'd, Advanced
- Interventions
- IBI363, Bevacizumab, Nab-paclitaxel
- First posted
- 2026-01-23
- Last updated
- 2026-01-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and Severity of Adverse Events | From first dose of study treatment until 90 days after the last dose or end of study, whichever occurs first. | Incidence, severity, and relationship to study treatment of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs), graded according to NCI CTCAE. Changes from baseline in 12-lead electrocardiogram (ECG), vital signs, physical examination findings, and clinical laboratory test results will also be assessed. |
| Primary | Overall Survival (OS) | 12 months after the last subject participating in | Overall Survival (OS per RECIST 1.1) is defined as the time from the starting date of study drug to the date of first documentation of death. |
| Secondary | Objective Response Rate (ORR) per RECIST v1.1 | 6 months after the last subject participating in | The proportion of subjects with complete response (CR) and partial response (PR) in total subjects |
| Secondary | Disease Control Rate (DCR) per RECIST v1.1 | 12 months after the last subject participating in | Disease control rate is defined as the proportion of patients with a best overall response of CR, PR, or stable disease (SD) according to RECIST v1.1 as assessed by investigators. |
| Secondary | Time to Response (TTR) | 12 months after the last subject participating in | Time to response is defined as the time from first dose of study treatment to the date of first documented CR or PR according to RECIST v1.1. |
| Secondary | Duration of Response (DoR) | 12 months after the last subject participating in | Duration of response is defined as the time from the first documented CR or PR to the first documented disease progression or death from any cause, according to RECIST v1.1. |
| Secondary | Progression-Free Survival (PFS) | 12 months after the last subject participating in | Progression-free survival is defined as the time from first dose of study treatment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07361991
GET https://conductscience.org/api/trials/v1/NCT07361991/registered